Quantcast

Latest Imides Stories

2011-12-12 12:50:55

Research on the same protein that was a primary mediator of the birth defects caused by thalidomide now holds hope in the battle against multiple myeloma, says the study's senior investigator, Keith Stewart, M.B., Ch.B. of Mayo Clinic in Arizona. Dr. Stewart presented the results at the 53rd annual meeting of the American Society of Hematology in San Diego. The drug thalidomide achieved infamy in the early 1960s as the cause of severe birth defects after being given to pregnant mothers for...

2011-08-11 07:30:00

ALISO VIEJO, Calif., Aug. 11, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that it has filed lawsuits in the U.S. District Court for the District of Delaware against Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc (collectively "Par") and Actavis South Atlantic LLC and Actavis, Inc. (collectively "Actavis"). The lawsuits were filed in response to Abbreviated New Drug Applications ("ANDAs") filed by Par and Actavis. In their...

2011-07-01 07:30:00

ALISO VIEJO, Calif., July 1, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) website indicates that an Abbreviated New Drug Application (ANDA) for a generic version of NUEDEXTA® (dextromethorphan hydrobromide and quinidine sulfate) capsules was submitted on March 7, 2011. The company received Paragraph IV certification notices on June 30, 2011. Avanir intends to vigorously enforce its...

2010-09-23 08:00:00

BURLINGTON, Mass., Sept. 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of multiple myeloma, more surveyed European hematologist-oncologists consider the combination of immunomodulatory agents and proteasome inhibitors promising with respect to efficacy than is the case for any other drug regimen combinations. In light of these findings, the emerging regimen of Onyx...

2009-12-07 07:01:00

NEW ORLEANS, Dec. 7 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced interim results from the Phase 1b/2 006 study, demonstrating that carfilzomib, when administered with the standard therapies lenalidomide (Revlimid®) and low dose dexamethasone, is active and well-tolerated in patients with relapsed and/or refractory multiple myeloma. These data were presented at the 51st annual meeting of the American Society of Hematology (ASH) in...

2009-11-17 11:25:29

'Renaissance' in use may lead to new treatments for controversial drug Research into the controversial drug thalidomide reveals that the mechanism through which the drug causes limb defects is the same process which causes it to damage internal organs and other tissues. The article, published in Bio-Essays, outlines the challenges surrounding thalidomide research and claims that confirmation of a 'common mechanism' could lead to new treatments for Leprosy, Crohn's Disease, AIDS and some forms...

2009-09-13 16:27:41

A British man Sunday said he will protest the government's refusal to compensate victims of the drug Thalidomide, administered to their mothers while pregnant. Gary Skyner, 49, of Liverpool, England, who was born with limb deformities because his mother was prescribed the anti-morning sickness drug, plans to begin a hunger strike in eight days, The Sunday Times of London reported. Skyner said the government refuses to provide additional compensation in addition to the annual compensation...

2009-08-25 09:53:00

NEW YORK, Aug. 25 /PRNewswire/ -- Beth R. Jacobson (formerly Beth R. Wolmer) filed suit yesterday against Celgene Corporation (Nasdaq: CELG), under the claims of "misappropriation of an idea" and "unjust enrichment" regarding the Company's sale of thalidomide (THALOMID(R) and REVLIMID(R)) for the treatment of multiple myeloma. The suit alleges that Ms. Jacobson developed the original and novel idea for treating multiple myeloma with thalidomide and is therefore entitled to compensation...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related